• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Female disadvantage in risk of adverse outcomes after incident diabetic foot hospitalizations: A population cohort study
CONCLUSIONS: After incident DFD hospitalizations, females with DFD associated with amputations or with arterial disease are burdened by a greater excess risk of subsequent adverse cardiovascular events, compared with those with background DFD.PMID:34455962 | DOI:10.2174/1573399817666210827121937
Source: Current Diabetes Reviews - August 30, 2021 Category: Endocrinology Authors: Giuseppe Seghieri Laura Policardo Elisa Gualdani Paolo Francesconi Source Type: research

Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
ConclusionPatient preferences for the benefits and risks of low-dose aspirin differ significantly among people eligible for treatment as primary or secondary CVD prevention.
Source: The Patient - Patient-Centered Outcomes Research - April 8, 2021 Category: International Medicine & Public Health Source Type: research

Prevalence and economic burden of major comorbidities in multiple sclerosis
ConclusionsOur study provides evidence of the burden of comorbidities in MS. Comorbidity is common in MS and produce additive costs.Key messagesThe use of administrative data for tracking the MS comorbidity could help knowledge gaps.When additivity situation is involved, preventive policies could lead to monetary savings.
Source: The European Journal of Public Health - October 20, 2021 Category: General Medicine Source Type: research